A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis

Phase 2 Not yet recruiting 111 enrolled Akeso

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe SAR

Timeline

Start: 2026-03-02
Primary completion: 2026-09-30
Completion: 2027-05-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AK139	Unknown	—	Subcutaneous

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis

Summary

Timeline

Drugs

Indications